Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
RedactPHI
HIPAA-Compliant PHI Redaction
DetectICD10CM
ICD-10-CM Code Detection
Log in Register free account
1 code page views remaining. Guest accounts are limited to 1 page view. Register free account to get 5 more views.
Log in Register free account

Official Description

Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach

© Copyright 2025 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 0660T refers to the implantation of a nonbiodegradable drug-eluting system within the anterior segment of the eye, utilizing an internal approach. This procedure involves the insertion of a specialized implant designed to deliver targeted intraocular therapy for various ocular conditions, particularly glaucoma. The implant is engineered to provide a continuous and long-term release of travoprost, a medication that effectively reduces intraocular pressure, which is crucial for managing glaucoma. By bypassing the corneal barrier, this method eliminates the reliance on patient compliance with traditional eyedrop regimens, thereby enhancing treatment efficacy. The titanium implant consists of a scleral anchor that secures the device to the trabecular meshwork, a drug reservoir that holds the medication, and a titrating elution membrane that controls the release of the drug into the anterior chamber. The procedure is performed through a small 2.4 mm incision, allowing for a minimally invasive approach to view the anterior chamber angle via an ab interno technique. This innovative method not only improves patient outcomes but also streamlines the management of glaucoma by providing a consistent therapeutic effect without the need for daily medication administration.

© Copyright 2025 Coding Ahead. All rights reserved.

1. Indications

The implantation of the anterior segment intraocular nonbiodegradable drug-eluting system is indicated for the treatment of various ocular conditions, particularly those associated with elevated intraocular pressure, such as:

  • Glaucoma A condition characterized by increased pressure within the eye, which can lead to optic nerve damage and vision loss.
  • Ocular Hypertension A condition where the intraocular pressure is higher than normal, increasing the risk of developing glaucoma.

2. Procedure

The procedure for the implantation of the drug-eluting system involves several critical steps to ensure proper placement and functionality of the device:

  • Step 1: Preparation The patient is positioned appropriately, and the eye is anesthetized to minimize discomfort during the procedure. A sterile field is established to prevent infection.
  • Step 2: Incision A small incision, approximately 2.4 mm in size, is made in the eye to access the anterior chamber. This micro-invasive approach is designed to reduce trauma to the surrounding tissues.
  • Step 3: Visualization The anterior chamber angle is visualized using an ab interno approach, allowing the surgeon to accurately position the implant within the eye.
  • Step 4: Implantation The scleral anchor of the titanium implant is carefully seated in the trabecular meshwork. The surgeon nudges the anchor to ensure it is securely attached, allowing for optimal drug delivery.
  • Step 5: Confirmation Once the implant is in place, the surgeon confirms its proper positioning and functionality before closing the incision.
  • Step 6: Post-Procedure Care After the procedure, the patient is monitored for any immediate complications, and instructions for post-operative care are provided.

3. Post-Procedure

Post-procedure care involves monitoring the patient for any signs of complications, such as infection or increased intraocular pressure. Patients may be advised to avoid strenuous activities and follow specific instructions regarding eye care. The titanium implant is designed to remain in place until the drug reservoir is depleted, at which point a similar micro-invasive surgical procedure can be performed for removal and reimplantation of the device. Regular follow-up appointments are essential to assess the effectiveness of the treatment and to ensure the ongoing health of the eye.

Short Descr IMPLT ANT SGM IO NBIO RX SYS
Medium Descr IMPLTJ ANT SGM IO NBIODEGRADABLE RX ELUTING SYS
Long Descr Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach
Status Code Carriers Price the Code
Global Days YYY - Carrier Determines Whether Global Concept Applies
PC/TC Indicator (26, TC) 0 - Physician Service Code
Multiple Procedures (51) 2 - Standard payment adjustment rules for multiple procedures apply.
Bilateral Surgery (50) 1 - 150% payment adjustment for bilateral procedures applies.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 1 - Statutory payment restriction for assistants at surgery applies to this procedure...
Co-Surgeons (62) 0 - Co-surgeons not permitted for this procedure.
Team Surgery (66) 0 - Team surgeons not permitted for this procedure.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Hospital Part B services paid through a comprehensive APC
ASC Payment Indicator Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight.
Berenson-Eggers TOS (BETOS) none
MUE 1
RT Right side (used to identify procedures performed on the right side of the body)
LT Left side (used to identify procedures performed on the left side of the body)
51 Multiple procedures: when multiple procedures, other than e/m services, physical medicine and rehabilitation services or provision of supplies (eg, vaccines), are performed at the same session by the same individual, the primary procedure or service may be reported as listed. the additional procedure(s) or service(s) may be identified by appending modifier 51 to the additional procedure or service code(s). note: this modifier should not be appended to designated "add-on" codes (see appendix d).
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
79 Unrelated procedure or service by the same physician or other qualified health care professional during the postoperative period: the individual may need to indicate that the performance of a procedure or service during the postoperative period was unrelated to the original procedure. this circumstance may be reported by using modifier 79. (for repeat procedures on the same day, see modifier 76.)
GA Waiver of liability statement issued as required by payer policy, individual case
JZ Zero drug amount discarded/not administered to any patient
SG Ambulatory surgical center (asc) facility service
Date
Action
Notes
2022-01-01 Added First appearance in codebook.
2021-07-01 Added Code added.
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"